Loading clinical trials...

A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION) | Clinical Trials | Clareo Health

COMPLETED

A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)

Retrospective Study to Evaluate the Impact of Using Interferon (Pegylated or Not) in the Treatment of Patients With Chronic Hepatitis C in Brazil (DECISION)

NCT01280656•Hoffmann-La Roche

View on ClinicalTrials.gov

Summary

This retrospective study will assess the sustained virologic response and the safety of two different interferons (pegylated or conventional) in patients with chronic hepatitis C. Data will be collected for 24 weeks.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult patients, \>/=18 years and \<70 years of age
•Diagnosis of hepatitis C
•Assessment of viral load prior to treatment (mandatory for genotype 1 only)
•Liver biopsy
•Co-morbidities data
•Use of interferon (pegylated or conventional) and ribavirin to treat hepatitis C infection genotype 2 and 3 and pegylated interferon plus ribavirin to treat hepatitis C infection genotype 1
•Above mentioned treatment started between 01-Sep-2007 and 31-Aug-2008

Exclusion Criteria

•Co-infection with human immunodeficiency virus
•Co-infection with hepatitis B virus
•Presence of hepatocarcinoma
•Patients submitted to hemodialysis
•Organ transplant patients

Locations (37)

Rio Branco, Acre, Brazil

Manaus, Amazonas, Brazil

Vitória, Espírito Santo, Brazil

Salvador, Estado de Bahia, Brazil

Goiânia, Goiás, Brazil

São Luís, Maranhão, Brazil

Campo Grande - MS, Mato Grosso do Sul, Brazil

Pouso Alegre, Minas Gerais, Brazil

Uberaba, Minas Gerais, Brazil

Curitiba, Paraná, Brazil

Key Dates

Start Date

January 1, 2010

Primary Completion Date

November 1, 2012

Completion Date

June 1, 2013

Last Updated

November 29, 2016

Enrollment

660

ACTUAL participants

Conditions

Hepatitis C, Chronic

Interventions

Conventional Interferon

DRUG

Peginterferon Alfa-2a

DRUG

Peginterferon Alfa-2b

DRUG

Ribavirin

DRUG

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

NCT05870969

Carcinoma, HepatocellularHepatitis C, Chronic+3 more

View study

COMPLETEDPHASE4

The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study

NCT03987503

Hepatitis C, Chronic

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 29, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)

Inclusion Criteria

Exclusion Criteria

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study

Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir

Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes

Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs

The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection